Spots Global Cancer Trial Database for pemetrexed disodium
Every month we try and update this database with for pemetrexed disodium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors | NCT00390000 | Unspecified Adu... | vatalanib pemetrexed diso... pharmacological... ultrasound imag... | 18 Years - | Mayo Clinic | |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | NCT03137771 | Recurrent Non-S... Stage IV Non-Sm... | 3-Dimensional C... Docetaxel Gemcitabine Intensity-Modul... Pemetrexed Diso... Stereotactic Bo... Erlotinib Hydro... Pembrolizumab | 18 Years - | NRG Oncology | |
| Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery | NCT00005636 | Malignant Mesot... | cisplatin pemetrexed diso... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer | NCT00520845 | Lung Cancer | celecoxib Docetaxel pemetrexed diso... laboratory biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | NCT00691301 | Cervical Cancer | cisplatin pemetrexed diso... | - 120 Years | GOG Foundation | |
| Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer | NCT01784640 | Recurrent Non-s... Squamous Cell L... Stage IV Non-sm... | Hsp90 inhibitor... pemetrexed diso... pharmacological... laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer | NCT00006007 | Breast Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer | NCT00410904 | Recurrent Non-s... | cediranib malea... pemetrexed diso... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer | NCT00117962 | Lung Cancer | cetuximab carboplatin pemetrexed diso... radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma | NCT01105390 | Advanced Malign... Epithelial Meso... Recurrent Malig... Sarcomatous Mes... | rilotumumab cisplatin pemetrexed diso... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer | NCT02535325 | Locally Advance... Stage III Lung ... Stage III Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... Stage IIIB Lung... Stage IIIB Lung... Stage IV Lung A... Stage IV Lung L... Stage IV Lung N... | 3-Dimensional C... Cisplatin Intensity-Modul... Methoxyamine Methoxyamine Hy... Pemetrexed Pemetrexed Diso... | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | NCT04061590 | Lung Non-Small ... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Cisplatin Pembrolizumab Pemetrexed Pemetrexed Diso... Therapeutic Con... | 18 Years - | University of California, San Francisco | |
| Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | NCT00387322 | Lung Cancer Unspecified Adu... | erlotinib hydro... pemetrexed diso... | 18 Years - | University of California, Davis | |
| Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery | NCT00541073 | Malignant Mesot... | vitamin B12 cisplatin pemetrexed diso... gene expression... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma | NCT00227630 | Malignant Mesot... | cisplatin pemetrexed diso... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | - 69 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | NCT02194738 | Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... | Biospecimen Col... Carboplatin Cisplatin Clinical Observ... Computed Tomogr... Crizotinib Cytology Specim... Echocardiograph... Erlotinib Gemcitabine Hyd... Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Diso... Placebo Adminis... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00798603 | Lung Cancer | bevacizumab carboplatin pemetrexed diso... | 70 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00268489 | Lung Cancer | bevacizumab pemetrexed diso... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer | NCT02535325 | Locally Advance... Stage III Lung ... Stage III Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... Stage IIIB Lung... Stage IIIB Lung... Stage IV Lung A... Stage IV Lung L... Stage IV Lung N... | 3-Dimensional C... Cisplatin Intensity-Modul... Methoxyamine Methoxyamine Hy... Pemetrexed Pemetrexed Diso... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers | NCT01344824 | Lung Cancer | bevacizumab carboplatin erlotinib hydro... pemetrexed diso... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma | NCT00101283 | Mesothelioma | pemetrexed diso... gemcitabine hyd... carboplatin | 18 Years - | Eastern Cooperative Oncology Group | |
| Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | NCT00702299 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | cisplatin paclitaxel pemetrexed diso... biologic sample... | 18 Years - | University of Arizona | |
| Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | NCT02693717 | Metastatic Urot... | Laboratory Biom... Pemetrexed Diso... | 18 Years - | M.D. Anderson Cancer Center | |
| Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | NCT02426658 | Stage IV Non-Sm... | Laboratory Biom... Pemetrexed Diso... Quality-of-Life... | 18 Years - | Wake Forest University Health Sciences | |
| Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer | NCT00227565 | Lung Cancer | carboplatin pemetrexed diso... radiation | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | NCT02607423 | Stage IIIA Non-... | Cisplatin Computed Tomogr... Docetaxel Fludeoxyglucose... Gemcitabine Hyd... Pemetrexed Diso... Positron Emissi... | 18 Years - | Eastern Cooperative Oncology Group | |
| AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer | NCT00410904 | Recurrent Non-s... | cediranib malea... pemetrexed diso... | 18 Years - | National Cancer Institute (NCI) | |
| Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery | NCT00005636 | Malignant Mesot... | cisplatin pemetrexed diso... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors | NCT00573690 | Unspecified Adu... | carboplatin cisplatin etoposide pemetrexed diso... sorafenib tosyl... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | NCT04895735 | Metastatic Sali... Recurrent Saliv... Stage IV Major ... Adenoid Cystic ... | Pembrolizumab Pemetrexed Diso... Biospecimen Col... Computed Tomogr... Positron Emissi... Magnetic Resona... PSMA PET Scan | 18 Years - | Mayo Clinic | |
| Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors | NCT00070473 | Unspecified Chi... | pemetrexed diso... | 1 Year - 21 Years | Children's Oncology Group | |
| Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer | NCT00117962 | Lung Cancer | cetuximab carboplatin pemetrexed diso... radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer | NCT00280748 | Lung Cancer Metastatic Canc... | pemetrexed diso... radiation thera... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer | NCT00301808 | Lung Cancer | Cisplatin Docetaxel Pemetrexed diso... Radiation thera... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | NCT00702299 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | cisplatin paclitaxel pemetrexed diso... biologic sample... | 18 Years - | University of Arizona | |
| Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer | NCT01338792 | Hormone-resista... Recurrent Prost... | oxaliplatin pemetrexed diso... questionnaire a... laboratory biom... reverse transcr... polymorphism an... | 18 Years - | University of Southern California | |
| Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | NCT00389805 | Lung Cancer Unspecified Adu... | bortezomib pemetrexed diso... gene expression... mutation analys... protein express... reverse transcr... flow cytometry immunoenzyme te... immunohistochem... | 18 Years - 120 Years | University of California, Davis | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | NCT02194738 | Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... | Biospecimen Col... Carboplatin Cisplatin Clinical Observ... Computed Tomogr... Crizotinib Cytology Specim... Echocardiograph... Erlotinib Gemcitabine Hyd... Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Diso... Placebo Adminis... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | NCT00950365 | Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Stage IIIB Non-... Stage IV Non-Sm... | Erlotinib Hydro... Laboratory Biom... Pemetrexed Diso... | 18 Years - | Albert Einstein College of Medicine | |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial | NCT04267848 | Lung Non-Small ... Lung Non-Small ... Lung Non-Squamo... Stage II Lung C... Stage IIIA Lung... Stage IIIB Lung... | Biospecimen Col... Carboplatin Cisplatin Computed Tomogr... Echocardiograph... Gemcitabine Hyd... Magnetic Resona... Observation Paclitaxel Pembrolizumab Pemetrexed Diso... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00438204 | Lung Cancer | bevacizumab gemcitabine hyd... pemetrexed diso... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma | NCT04158141 | Pleural Biphasi... Pleural Epithel... Stage I Pleural... Stage IA Pleura... Stage IB Pleura... Stage II Pleura... Stage IIIA Pleu... | Carboplatin Cisplatin Decortication Intensity-Modul... Pemetrexed Pemetrexed Diso... Pencil Beam Sca... Pleurectomy Quality-of-Life... Questionnaire A... | 18 Years - 80 Years | NRG Oncology | |
| Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer | NCT01958372 | Adenocarcinoma ... Adenosquamous C... Bronchoalveolar... Large Cell Lung... Recurrent Non-s... Squamous Cell L... Stage IIIA Non-... Stage IIIB Non-... | soy isoflavones cisplatin etoposide pemetrexed diso... radiation thera... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer | NCT00573989 | Head and Neck C... | erlotinib hydro... pemetrexed diso... quality-of-life... intensity-modul... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | NCT02134912 | Adenocarcinoma ... Large Cell Lung... Recurrent Non-s... Stage IV Non-sm... | crizotinib pemetrexed diso... laboratory biom... pharmacological... | 18 Years - | SWOG Cancer Research Network | |
| Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00320073 | Unspecified Adu... | erlotinib hydro... pemetrexed diso... vinflunine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function | NCT00003706 | Unspecified Adu... | pemetrexed diso... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | NCT04092283 | Recurrent Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Unresectable Lu... | Carboplatin Cisplatin Durvalumab Etoposide Paclitaxel Pemetrexed Diso... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer | NCT00059865 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | NCT02426658 | Stage IV Non-Sm... | Laboratory Biom... Pemetrexed Diso... Quality-of-Life... | 18 Years - | Wake Forest University Health Sciences | |
| Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer | NCT01041781 | Lung Cancer | carboplatin celecoxib gemcitabine hyd... pemetrexed diso... placebo | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer | NCT00087100 | Endometrial Can... | pemetrexed diso... | - | GOG Foundation | |
| LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function | NCT00003706 | Unspecified Adu... | pemetrexed diso... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | NCT01935947 | Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Azacitidine Azacitidine Docetaxel Entinostat Gemcitabine Hyd... Irinotecan Hydr... Laboratory Biom... Pemetrexed Diso... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | NCT04092283 | Recurrent Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Unresectable Lu... | Carboplatin Cisplatin Durvalumab Etoposide Paclitaxel Pemetrexed Diso... | 18 Years - | National Cancer Institute (NCI) | |
| Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | NCT03228537 | Biphasic Mesoth... Epithelioid Mes... Stage I Pleural... Stage IA Pleura... Stage IB Pleura... Stage II Pleura... Stage III Pleur... | Atezolizumab Cisplatin Extrapleural Pn... Pemetrexed Diso... Pleurectomy Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer | NCT01723800 | Recurrent Non-s... Stage IV Non-sm... | PI3K inhibitor ... pemetrexed diso... carboplatin laboratory biom... pharmacological... quality-of-life... | 18 Years - | City of Hope Medical Center | |
| Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer | NCT00573989 | Head and Neck C... | erlotinib hydro... pemetrexed diso... quality-of-life... intensity-modul... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | NCT00691301 | Cervical Cancer | cisplatin pemetrexed diso... | - 120 Years | GOG Foundation | |
| Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer | NCT01784640 | Recurrent Non-s... Squamous Cell L... Stage IV Non-sm... | Hsp90 inhibitor... pemetrexed diso... pharmacological... laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer | NCT01958372 | Adenocarcinoma ... Adenosquamous C... Bronchoalveolar... Large Cell Lung... Recurrent Non-s... Squamous Cell L... Stage IIIA Non-... Stage IIIB Non-... | soy isoflavones cisplatin etoposide pemetrexed diso... radiation thera... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors | NCT00573690 | Unspecified Adu... | carboplatin cisplatin etoposide pemetrexed diso... sorafenib tosyl... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | NCT00698815 | Recurrent Non-S... Stage IIIB Non-... Stage IV Non-Sm... | Laboratory Biom... Pemetrexed Diso... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | NCT04895735 | Metastatic Sali... Recurrent Saliv... Stage IV Major ... Adenoid Cystic ... | Pembrolizumab Pemetrexed Diso... Biospecimen Col... Computed Tomogr... Positron Emissi... Magnetic Resona... PSMA PET Scan | 18 Years - | Mayo Clinic | |
| Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | NCT00691301 | Cervical Cancer | cisplatin pemetrexed diso... | - 120 Years | GOG Foundation | |
| Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00438204 | Lung Cancer | bevacizumab gemcitabine hyd... pemetrexed diso... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | NCT00227539 | Lung Cancer | cisplatin pemetrexed diso... adjuvant therap... therapeutic con... fludeoxyglucose... | 18 Years - 120 Years | University of Washington | |
| Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer | NCT00738881 | Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Erlotinib Hydro... Pemetrexed Diso... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | NCT00053209 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | NCT00703638 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Mesothelioma Pancreatic Canc... Prostate Cancer Sarcoma | cisplatin pemetrexed diso... sorafenib | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy | NCT00096187 | Gestational Tro... | pemetrexed diso... | - 120 Years | GOG Foundation | |
| Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors | NCT00003711 | Unspecified Adu... | irinotecan hydr... pemetrexed diso... | 18 Years - | National Cancer Institute (NCI) | |
| Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | NCT02607423 | Stage IIIA Non-... | Cisplatin Computed Tomogr... Docetaxel Fludeoxyglucose... Gemcitabine Hyd... Pemetrexed Diso... Positron Emissi... | 18 Years - | Eastern Cooperative Oncology Group | |
| Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | NCT03366766 | Non-Squamous No... Stage I Non-Sma... Stage IA Non-Sm... Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Nivolumab Cisplatin Pemetrexed Diso... Gemcitabine Hyd... | 18 Years - | Thomas Jefferson University | |
| Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | NCT00387322 | Lung Cancer Unspecified Adu... | erlotinib hydro... pemetrexed diso... | 18 Years - | University of California, Davis | |
| Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | NCT03366766 | Non-Squamous No... Stage I Non-Sma... Stage IA Non-Sm... Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Nivolumab Cisplatin Pemetrexed Diso... Gemcitabine Hyd... | 18 Years - | Thomas Jefferson University | |
| Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer | NCT00503997 | Head and Neck C... | oxaliplatin pemetrexed diso... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00798603 | Lung Cancer | bevacizumab carboplatin pemetrexed diso... | 70 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00268489 | Lung Cancer | bevacizumab pemetrexed diso... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery | NCT00324805 | Stage IB Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Bevacizumab Cisplatin Docetaxel Gemcitabine Hyd... Laboratory Biom... Pemetrexed Diso... Questionnaire A... Vinorelbine Tar... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
